EXEL Exelixis Inc.

20.9
-0.46  -2%
Previous Close 21.36
Open 21.32
Price To Book 4.89
Market Cap 6272709267
Shares 300,129,630
Volume 4,162,462
Short Ratio
Av. Daily Volume 3,337,362

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2019.
IMspire170 - cobimetinib and atezolizumab
First-line BRAF wild-type metastatic or unresectable locally advanced melanoma
Phase 3 data released May 10, 2018. Primary endpoint not met.
IMblaze370 - cobimetinib and atezolizumab
Third-line advanced or metastatic colorectal cancer
Phase 2 ongoing.
CABOMETYX (cabozantinib)
Recurrent endometrial cancer
Phase 3 data due 2H 2019.
CABOMETYX (cabozantinib) with Opdivo and Yervoy - CheckMate 9ER
First-line renal cell carcinoma
Approved November 29, 2012.
Cabozantinib
Medullary thyroid cancer
Phase 3 trial met primary endpoint - September 24, 2017. Japanese regulatory filing due 1Q 2018.
Esaxerenone (CS-3150)
Essential hypertension
Late breaker at ESMO September 10, 2017 showed PFS 8.6 months versus 5.3 months for sunitinib. HR 0.48. PDUFA date under priority review for sNDA February 15, 2018. Approval announced December 19, 2017.
Cabozantinib - CABOSUN
First-Line RCC - cancer
FDA Approval announced January 14, 2019.
Cabozantinib (CELESTIAL)
Advanced hepatocellular cancer (HCC)
Approved April 25 2016.
CABOMETYX (cabozantinib)
Metastatic renal cell cancer (RCC)
Approved November 10, 2015.
Vemurafenib
BRAF V600 Mutation-Positive Advanced Melanoma - Cancer
Phase 3 COMET-2 trial did not meet endpoint December 1 2014
Cabozantinib
Cancer - Castration-Resistant Prostate Cancer
Phase 3 trial initiation announced October 8, 2018.
Cabozantinib
Thyroid Carcinoma
Phase 1 presentation at ASCO 2018.
CABOMETYX (cabozantinib) + Nivolumab and Ipilimumab
Urothelial Carcinoma
Phase 3 data due 2019.
IMspire150 - cobimetinib, atezolizumab and vemurafenib - TRILOGY
BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma
Phase 1b trial expansion announced June 1, 2018.
Cabozantinib + atezolizumab (TECENTRIQ) COSMIC-021
Solid tumors
Phase 3 initiation announced December 5, 2018.
CABOMETYX (cabozantinib) + atezolizumab (TECENTRIQ) - (COSMIC-312)
Hepatocellular Carcinoma
Phase 1 trial initiation announced February 12, 2019.
XL092
Solid tumors

Latest News

  1. Exelixis to Release First Quarter 2019 Financial Results on Wednesday, May 1, 2019
  2. ProQR Initiates Dosing in Phase II/III Eye Disorder Study
  3. Has Exelixis, Inc. (NASDAQ:EXEL) Got Enough Cash?
  4. Risk-Tolerant Investors, Turn Your Eyes to Exelixis Stock
  5. See what the IHS Markit Score report has to say about Exelixis Inc.
  6. Exelixis (EXEL) Rallies 22.4% YTD: What to Expect Ahead?
  7. Exelixis to Present at the 18th Annual Needham Healthcare Conference on April 10, 2019
  8. The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage
  9. Market Trends Toward New Normal in 3M, Exelixis, Wright Medical Group N.V, MSA Safety Incorporated, Principal Financial Group, and Portland General Electric — Emerging Consolidated Expectations, Analyst Ratings
  10. Morgan Stanley Drops Bearish Exelixis Stance, Sees 'Limited Downside Risk'
  11. Signal Says Buy Options Insurance on This Biotech
  12. Exelixis (EXEL) Gains As Market Dips: What You Should Know
  13. How a biotech company navigated bay bureaucracy to set up a commuter ferry service
  14. Why Is Exelixis (EXEL) Up 12.1% Since Last Earnings Report?
  15. 5 Biotech Stocks to Keep an Eye on in 2019
  16. Why Exelixis, Inc. (NASDAQ:EXEL) Is An Attractive Investment To Consider
  17. Pfizer's (PFE) Kidney Cancer Drug Combo Gets EMA's Validation
  18. Exelixis (EXEL) Dips More Than Broader Markets: What You Should Know
  19. Exelixis Announces Webcasts of Investor Conference Presentations in March